Collectively, our study revealed that structural hybridization strategies yielded novel and potential c-MET/EGFR/PI3K/mTOR multi-target compounds, NSC777205 and NSC777205, with promising prospects for treating melanoma, renal, CNS, colon, and NSCLC cell lines. Here, MTOR is linked to non-small cell lung carcinoma.